GW 501-516 (20MG)

GlaxoSmithKline, a multinational pharmaceutical company, originally developed GW 501-516 Cardarine to treat hyperlipidemia, obesity, metabolic dysfunction, and cardiac disease.

GW 501-516 Cardarine, also known as Endoburol and Cardarine, is often used in studies as a PPARδ agonist.

As PPARδ plays an important role in mitochondrial respiration, temperature regulation, inflammation mediation, skin and muscle repair, skeletal reprogramming, and keratinocyte differentiation.

A number of studies have shown that GW 501-516 affects fatty acid metabolism, skeletal muscle endurance, and glucose/insulin balance.

One study clearly demonstrates the impact of GW 501-516 in the endurance levels of both trained and untrained (sedentary prior to the study) mouse subjects.

After three weeks of GW 501-516, the trained test subjects demonstrated a 31.2% increase in their total run distance, whereas the untrained test subjects increased their total distance by 68.6%.

The trained group that received GW 501-516 had higher usage of longer saturated fatty acids, as well as triglycerides, and were shown to enhance running endurance. This is likely due to the increased fatty acid metabolism after implementing GW 501-516 which up-regulates mediating pathways of fatty acid oxidation.

Molecular analysis revealed that GW 501-516 is involved in exercise-induced reprogramming of muscle fibers and skeletal muscle metabolism. This is because GW 501-516 regulates the expression of genes associated with contractile proteins, mitochondrial biogenesis, and lipid oxidation.

Another study confirmed the findings above by administering GW 501-516 to mice who were also fed a high-fat diet. This group only experienced a slight weight loss but metabolic markers were noted such as decreased insulin resistance, increased metabolic rate, increased mitochondria, and reduced lipids in skeletal muscle. Furthermore, the genetically obese mice in the study also had decreased glucose and insulin levels.

One study indicated that GW 501-516 may also play a role in reducing inflammation, specifically in the liver. For rats fed a high-fructose diet, GW 501-516 reduced the inflammation markers for the highly activated ACE/AT1r axis. Additionally, it increased the prevalence of the genes that regulate beta-oxidation and decreased those that regulate fat cells as well as glucose creation. 

Similar results were noted in a primate study, where middle-aged, overweight to obese rhesus monkeys were given GW 501-516. Testing indicated that GW 501-516 caused a dramatic dose-dependent rise in serum HDL cholesterol while lowering the levels of LDL, fasting triglycerides, and fasting insulin levels. The research suggests that GW 501-516 may be an effective treatment method to increase reverse cholesterol transport and decrease cardiovascular disease associated with certain metabolic syndromes.

The primary concern for SARMs researchers today is product purity.  Nordsci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.

THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION

ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY